Myriad Genetics bets on neuroscience with 5 million acquisition

Dive Brief:Myriad Genetics announced Wednesday it had acquired Assurex Health for $225 million upfront plus $185 million in milestone payments. Assurex’s lead product, GeneSight Psychotropic, tests how a patient’s genes affect the body’s response to different treatment options.  The acquisition is an opportunity for Myriad to expand its presence to the neuroscience space ahead of the company’s potential 2019 release of MyPath Bipolar, a diagnostic test aimed at distinguishing bipolar disorder from depression. Myriad hopes it can leverage GeneSight’s sales force to boost the product’s launch. More than 76 million people have mental disorders in the U.S., and the country’s healthcare system spends over $150 billion a year to treat these disorders, according to the company. Depression represents a quarter of this market, and another 5 million people have bipolar disorder. …


Link to Full Article: Myriad Genetics bets on neuroscience with 5 million acquisition